GlaxoSmithKline, Binnopharm enter vaccine deal in Russia

GlaxoSmithKline announced a deal with Binnopharm that will allow the Russian drugmaker to manufacture and market GlaxoSmithKline's vaccines Cervarix, Rotarix, and Synflorix, in its domestic market. Abbas Hussain, head of emerging markets and Asia Pacific for GlaxoSmithKline, said the "agreement is an example of the flexible approach we are taking to make innovative vaccines more available in emerging markets through local partnerships."
Under the deal, GlaxoSmithKline said it will supply bulk vaccine, as well as technology to produce the products, while Binnopharm will undertake manufacturing, including filling and packaging. The companies noted that the collaboration should increase sales of the vaccines, which will be marketed and branded under Binnopharm's trademark for the public market. GlaxoSmithKline will record sales of the bulk vaccines supplied to Binnopharm, although no further financial details were provided.
The two companies noted that "the local manufacture of these vaccines should help Russia to modernise its National Immunisation Calendar in the future."
>
Latin America -- find out what strategies pharmaceutical marketers are using in these emerging markets.
Pharma Marketing in Latin America - click here to find out more

Reference Articles
GSK and Binnopharm agree vaccine deal in Russia - (Forexpros)
GlaxoSmithKline and JSC Binnopharm enter vaccine production alliance in Russia - (GlaxoSmithKline)
Russia's Binnopharm and GSK to cooperate in vaccine production - Kudrin - (RIA Novosti)
Companies cooperate to create vaccines - (The Moscow Times)
GlaxoSmithKline, Binnopharm form Russian vaccine production alliance (free preview) - (The Wall Street Journal)

**Published in "First Word"